2.86
Relay Therapeutics Inc stock is traded at $2.86, with a volume of 420.66K.
It is up +0.18% in the last 24 hours and down -8.36% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$2.845
Open:
$2.78
24h Volume:
420.66K
Relative Volume:
0.17
Market Cap:
$489.49M
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-1.0214
EPS:
-2.8
Net Cash Flow:
$-304.44M
1W Performance:
+1.42%
1M Performance:
-8.36%
6M Performance:
-40.00%
1Y Performance:
-59.17%
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
399 BINNEY STREET, CAMBRIDGE
Compare RLAY with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
RLAY
Relay Therapeutics Inc
|
2.855 | 478.33M | 25.55M | -341.97M | -304.44M | -2.80 |
![]()
ONC
Beigene Ltd Adr
|
241.48 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
434.98 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.78 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
74.84 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
Sep-10-24 | Resumed | Goldman | Buy |
Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
Apr-13-23 | Initiated | Raymond James | Outperform |
Feb-03-23 | Initiated | Oppenheimer | Outperform |
Sep-30-22 | Initiated | Barclays | Equal Weight |
Sep-02-22 | Initiated | Stifel | Buy |
Jun-06-22 | Initiated | Jefferies | Underperform |
Feb-01-22 | Initiated | Berenberg | Buy |
Jul-21-21 | Initiated | BofA Securities | Buy |
Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
Nov-05-20 | Initiated | H.C. Wainwright | Buy |
Aug-10-20 | Initiated | Cowen | Outperform |
Aug-10-20 | Initiated | Goldman | Buy |
Aug-10-20 | Initiated | Guggenheim | Buy |
Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Northern Trust Corp Buys 231,713 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
BNP Paribas Financial Markets Invests $987,000 in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Stifel Financial Corp Makes New Investment in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Transcript : Relay Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com
Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now - Yahoo Finance
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
HC Wainwright Issues Optimistic Forecast for RLAY Earnings - Defense World
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory - MSN
89,949 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Purchased by First Trust Advisors LP - Defense World
Dimensional Fund Advisors LP Grows Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Q2 EPS Estimate for Relay Therapeutics Lowered by Analyst - Defense World
Relay Therapeutics to Participate in Two Upcoming Investor Conferences - The Manila Times
Hsbc Holdings PLC Has $458,000 Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - The AM Reporter
MetLife Investment Management LLC Grows Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Guggenheim Lowers Price Target for Relay Therapeutics (RLAY) to $10.00 | RLAY Stock News - GuruFocus
Relay Therapeutics (RLAY) Stock Target Reduced Amid Strategic Changes and Progress | RLAY Stock News - GuruFocus
Marshall Wace LLP Lowers Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Raymond James Financial Inc. Takes $779,000 Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Wells Fargo & Company MN Decreases Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics Inc (RLAY) Q1 2025 Earnings: EPS Loss of $0.4 - GuruFocus
Relay Therapeutics (RLAY) Reports Decline in Q1 Revenue | RLAY S - GuruFocus
Relay Therapeutics Extends Cash Runway and Advances Clinical Trials - TipRanks
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates | RLAY Stock News - GuruFocus
Relay Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Relay Therapeutics, Inc. SEC 10-Q Report - TradingView
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates - The Manila Times
Relay Therapeutics Extends Cash Runway into 2029 Amid Clinical Trial Advancements - Nasdaq
Barclays PLC Has $1.29 Million Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Invesco Ltd. Acquires 5,261 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
There Is A Lot Of Upside Potential For Relay Therapeutics Inc(NASDAQ: RLAY) - Stocksregister
why Relay Therapeutics Inc [RLAY] is a Good Choice for Investors After New Price Target of $17.40 - dbtnews.com
Relay Therapeutics executive sells $36,540 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics executive sells $36,540 in stock - Investing.com Australia
LPL Financial LLC Sells 6,564 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics president sells $95,381 in stock By Investing.com - Investing.com South Africa
Relay Therapeutics chief legal officer sells $44,040 in stock By Investing.com - Investing.com South Africa
Relay Therapeutics CFO sells shares worth $44,246 By Investing.com - Investing.com South Africa
Relay Therapeutics Inc Stock: Executives Sell Shares Amid Mixed Signals - sharewise
Relay Therapeutics president sells $95,381 in stock - Investing.com Australia
Relay Therapeutics CFO sells shares worth $44,246 - Investing.com Australia
Relay Therapeutics chief legal officer sells $44,040 in stock - Investing.com
Relay Therapeutics Executives Sell Shares to Cover Tax Obligations and Under Trading Plan - TradingView
Healthy Upside Potential: Relay Therapeutics Inc (RLAY) - Sete News
Trading Day Review: Relay Therapeutics Inc (RLAY) Loses Momentum, Closing at 3.10 - DWinneX
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relay Therapeutics Inc Stock (RLAY) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Rahmer Peter | See remarks |
Apr 28 '25 |
Sale |
3.17 |
1,364 |
4,324 |
400,820 |
Catinazzo Thomas | Chief Financial Officer |
Apr 30 '25 |
Sale |
3.00 |
12,943 |
38,829 |
355,376 |
Catinazzo Thomas | Chief Financial Officer |
Apr 29 '25 |
Sale |
3.23 |
3,558 |
11,492 |
368,319 |
Catinazzo Thomas | Chief Financial Officer |
Apr 28 '25 |
Sale |
3.17 |
2,690 |
8,527 |
371,877 |
Bergstrom Donald A | President, R&D |
Apr 30 '25 |
Sale |
3.00 |
27,472 |
82,416 |
583,490 |
Bergstrom Donald A | President, R&D |
Apr 28 '25 |
Sale |
3.17 |
4,090 |
12,965 |
610,962 |
Adams Brian | Chief Legal Officer |
Apr 30 '25 |
Sale |
3.00 |
12,943 |
38,829 |
391,385 |
Adams Brian | Chief Legal Officer |
Apr 28 '25 |
Sale |
3.17 |
1,644 |
5,211 |
404,328 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):